-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Downgrades Contineum Therapeutics to Equal-Weight, Lowers Price Target to $14

Benzinga·01/08/2026 12:19:51
语音播报
Morgan Stanley analyst Jeffrey Hung downgrades Contineum Therapeutics (NASDAQ:CTNM) from Overweight to Equal-Weight and lowers the price target from $23 to $14.